Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

Fabry Disesase: early-phase trial registry

1 of 1 indexed Fabry Disesase trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · 1 currently recruiting · #11,370 of 28,707 conditions by registered trial count

Fabry Disesase: 1 US clinical trial tracked, 1 recruiting.

Fabry Disesase is the subject of 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is GC Biopharma, running 1 of these trials.

Enrollment posture brief

Registry condition fabry-disesase

OPEN 1 | RECR 100% | LATE 0 | EARLY 1 | RANK #11370 | SPON 1

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

Fabry Disesase (this)100%Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Fabry Disesase

Fabry Disesase lists 1 open slots (100% of 1 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Fabry Disesase on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Fabry Disesase is recruiting above its size-band peers.

    1 of 1 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 11

Phase Distribution

PhaseTrial count
Phase 1 1

Top Sponsors

GC Biopharma 1 trials

Named interventions

Most-linked intervention names on Fabry Disesase records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

HM15421/GC1134A Drug
1 trials

US sites by state

Facility locations filed on Fabry Disesase trials. A trial with sites in several states counts in each.

Virginia 1 trials
Pennsylvania 1 trials
Ohio 1 trials
Minnesota 1 trials
Kansas 1 trials
California 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Fabry Disesase page

1 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 1 Fabry Disesase trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • GC Biopharma sponsors the most Fabry Disesase trials on record, review their full trial history before evaluating a specific study. See GC Biopharma's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Fabry Disesase condition card totals 1 registered trials; most-linked intervention HM15421/GC1134A; top US site state Virginia. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.